
CAS 1044707-29-0: 1-Piperazineacetamide, N-(1,1-dimethylethyl)-, hydrochloride (1:2)
Description:1-Piperazineacetamide, N-(1,1-dimethylethyl)-, hydrochloride (1:2) is a chemical compound characterized by its piperazine and acetamide functional groups, which contribute to its potential biological activity. The presence of the N-(1,1-dimethylethyl) substituent indicates a bulky alkyl group that may influence the compound's lipophilicity and steric properties, potentially affecting its interaction with biological targets. As a hydrochloride salt, it is likely to be more soluble in water compared to its free base form, enhancing its bioavailability for pharmaceutical applications. The compound may exhibit properties such as being a potential therapeutic agent, with implications in medicinal chemistry, particularly in the development of drugs targeting neurological or psychiatric disorders. Its specific interactions, mechanisms of action, and pharmacokinetic profiles would require further investigation through experimental studies. Overall, this compound represents a class of piperazine derivatives that are of interest in drug discovery and development.
Formula:C10H21N3O·2ClH
InChI:InChI=1S/C10H21N3O.2ClH/c1-10(2,3)12-9(14)8-13-6-4-11-5-7-13;;/h11H,4-8H2,1-3H3,(H,12,14);2*1H
InChI key:InChIKey=DRBNGRMRFXBUEE-UHFFFAOYSA-N
SMILES:Cl.O=C(NC(C)(C)C)CN1CCNCC1
- Synonyms:
- 1-Piperazineacetamide, N-(1,1-dimethylethyl)-, hydrochloride (1:2)
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
![]() | N-(tert-butyl)-2-(1-piperazinyl)acetamide dihydrochloride REF: 10-F359768CAS: 1044707-29-0 | 95.0% | To inquire | Thu 24 Apr 25 |
![]() | N-tert-Butyl-2-(piperazin-1-yl)acetamide dihydrochloride REF: 3D-URB70729CAS: 1044707-29-0 | Min. 95% | - - - | Discontinued product |

N-(tert-butyl)-2-(1-piperazinyl)acetamide dihydrochloride
Ref: 10-F359768
1g | To inquire |

N-tert-Butyl-2-(piperazin-1-yl)acetamide dihydrochloride
Ref: 3D-URB70729
250mg | Discontinued | Request information | |
2500mg | Discontinued | Request information |